sorafenib has been researched along with interleukin-8 in 6 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (interleukin-8) | Trials (interleukin-8) | Recent Studies (post-2010) (interleukin-8) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 23,523 | 1,167 | 9,990 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bertolotto, C; Bourcier, C; Grépin, R; Griseri, P; Mazure, N; Pagès, G | 1 |
| Enomoto, M; Fujii, H; Hagihara, A; Iida-Ueno, A; Kawada, N; Morikawa, H; Murakami, Y; Tamori, A; Teranishi, Y; Thuy, LTT; Uchida-Kobayashi, S | 1 |
| Cetin-Atalay, R; Kahraman, DC; Kahraman, T | 1 |
| An, D; Annunziata, CM; Cao, L; Chen, H; Choyke, P; Hays, JL; Kohn, EC; Lee, JM; Minasian, LM; Steinberg, SM; Turkbey, IB; Wright, J; Yu, M | 1 |
| Basu, B; Ben Khaled, N; Benckert, J; Berg, T; de Toni, EN; Gasbarrini, A; Jurkeviciute, G; Klümpen, HJ; Kupčinskas, J; Malfertheiner, P; Morkunas, E; Öcal, O; Palmer, D; Pech, M; Ricke, J; Sangro, B; Schütte, K; Seidensticker, M; Seidensticker, R; Sengel, C; Valle, JW; Wildgruber, M | 1 |
| Górka, J; Hoffman, RM; Jura, J; Kwapisz, O; Marona, P; Miekus, K; Rys, J | 1 |
2 trial(s) available for sorafenib and interleukin-8
| Article | Year |
|---|---|
Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Interleukin-8; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Progression-Free Survival; Response Evaluation Criteria in Solid Tumors; Sorafenib | 2020 |
Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Disease Progression; Europe; Female; Follow-Up Studies; Humans; Interleukin-6; Interleukin-8; Liver Neoplasms; Male; Middle Aged; Predictive Value of Tests; Prognosis; Sorafenib; Survival Analysis; Turkey; Young Adult | 2022 |
4 other study(ies) available for sorafenib and interleukin-8
| Article | Year |
|---|---|
Constitutive ERK activity induces downregulation of tristetraprolin, a major protein controlling interleukin8/CXCL8 mRNA stability in melanoma cells.
Topics: Animals; Antibodies; Antineoplastic Agents; Apoptosis; Autophagy; Benzamides; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Chemokine CXCL1; Chemokine CXCL5; Dichlororibofuranosylbenzimidazole; Down-Regulation; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression; Genes, Reporter; Half-Life; Humans; Immunotherapy, Active; Interleukin-8; Leupeptins; MAP Kinase Kinase Kinases; Melanoma; Membrane Proteins; Mice; Mice, Inbred BALB C; Microtubule-Associated Proteins; Niacinamide; Phenylurea Compounds; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins; Pyridines; Receptors, Interleukin-8B; RNA Stability; RNA, Messenger; RNA, Small Interfering; Sorafenib; Transfection; Tristetraprolin; Tumor Cells, Cultured; Vaccination | 2011 |
Changes in plasma interleukin-8 and tumor necrosis factor-α levels during the early treatment period as a predictor of the response to sorafenib in patients with unresectable hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Interleukin-8; Liver Neoplasms; Male; Predictive Value of Tests; Retrospective Studies; Sorafenib; Survival Analysis; Tumor Necrosis Factor-alpha | 2018 |
Targeting PI3K/Akt/mTOR Pathway Identifies Differential Expression and Functional Role of IL8 in Liver Cancer Stem Cell Enrichment.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Interleukin-8; Liver Neoplasms; Neoplastic Stem Cells; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Sirolimus; Sorafenib; Sulfonamides; TOR Serine-Threonine Kinases | 2019 |
Resistance to tyrosine kinase inhibitors promotes renal cancer progression through MCPIP1 tumor-suppressor downregulation and c-Met activation.
Topics: Cadherins; Carcinoma, Renal Cell; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Humans; Interleukin-6; Interleukin-8; Kidney; Kidney Neoplasms; Matrix Metalloproteinase 9; Neovascularization, Pathologic; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Ribonucleases; Sorafenib; Sunitinib; Transcription Factors | 2022 |